The annual report of the company was released on April 27, 2024, with a year-on-year increase of RMB 685.2 billion; The net profit attributable to the shareholders of the listed company was 108 million yuan, a year-on-year increase of 198.82%; The net profit attributable to the shareholders of the listed company after deducting non recurring profits and losses was 966601 million yuan, a year-on-year increase of 253.54%; The basic earnings per share is 0.28 yuan.
For the growth of operating revenue, the company said that it was mainly due to the increase in the sales volume of adsorbed tetanus vaccine compared with the same period of last year, resulting in incremental revenue; At the same time, the company’s AC conjugate vaccine was issued and marketed for the first time, bringing sales revenue to the company. The increase of net profit is mainly due to the increase of sales scale.
Chengdu Olymvax Biopharmaceuticals Inc(688319) is a high-tech enterprise focusing on the R & D, production and sales of human vaccines. At present, the company has three products on the market, namely adsorbed tetanus vaccine, Hib conjugate vaccine and AC conjugate vaccine. At the same time, the company has AC Hib conjugate vaccine in the production status to be declared and Staphylococcus aureus vaccine in the clinical trial stage.
The annual report shows that at present, only companies in China and Wuhan biological produce adsorbed tetanus vaccine. As the adsorbed tetanus vaccine mainly sold for non neonatal tetanus in the Chinese market, the sales volume of the company’s product is expected to grow in the future; AC Hib combined vaccine can effectively reduce the number of vaccination, and has the advantages of good compliance and high cost performance. At present, the AC Hib combined vaccine under research by the company is preparing to apply for production; The recombinant Staphylococcus aureus vaccine developed by the company in cooperation with the Army Medical University is the only recombinant Staphylococcus aureus vaccine to carry out clinical research in China, and phase II clinical trials have been completed. The vaccine is suitable for people at high risk of Staphylococcus aureus infection, including perioperative patients, the elderly and children with low immunity. It is expected that the vaccine market will be very broad in the future.
